AMENDMENT TO THE LICENSE AGREEMENT BY AND BETWEEN HYBRIDON, INC. AND YOON S. CHO-CHUNG, M.D., PH.D.The License Agreement • March 25th, 2005 • Hybridon Inc • Biological products, (no disgnostic substances)
FIRST AMENDMENT TO THE LICENSE AGREEMENTThe License Agreement • January 20th, 2010 • Universal City Travel Partners • Services-amusement & recreation services • New York
This FIRST AMENDMENT TO THE LICENSE AGREEMENT is made and entered into as of May 25, 2007 (this “Amendment”), by and among Universal Studios, Inc., a Delaware corporation (“USI”), Universal City Studios LLLP, a Delaware limited liability limited partnership (formerly known as Universal City Studios, Inc., “UCS”), Universal City Property Management Company II LLC, a Delaware limited liability company (formerly known as Universal City Property Management II, “UniCo”) and Universal City Development Partners, Ltd., a Florida limited partnership (“UCDP Ltd.,” formerly known as Universal City Development Partners, LP (“UCDP LP”)).
AMENDMENT NO. 2 TO THE LICENSE AGREEMENT BETWEEN INTRINSIC MEDICINE, INC. (FKA LUPA BIO, INC.) AND THE REGENTS OF THE UNIVERSITY OF CALIFORNIAThe License Agreement • April 8th, 2022 • Intrinsic Medicine, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 2 to the License Agreement (this “Amendment No. 2”) is entered into by and between Intrinsic Medicine, Inc. (fka Lupa Bio, Inc.) (hereinafter “LICENSEE”) and the Regents of the University of California (“UNIVERSITY”) represented by its San Diego campus (“UC San Diego”), each referred to herein as a “Party”, or collectively as the “Parties”. Capitalized terms used herein and not otherwise defined have the meanings ascribed to them in the License Agreement.
SECOND AMENDMENT TO THE LICENSE AGREEMENTThe License Agreement • March 11th, 2024 • Lirum Therapeutics, Inc. • Pharmaceutical preparations
This Second Amendment to the License Agreement (this “Second Amendment”) is made and entered into this 11th day of July 2023, by and among IGF Oncology, LLC, a Delaware limited liability company (“IGF”), and Lirum Therapeutics, Inc., a Delaware corporation (“LIRUM”). IGF and LIRUM are from time to time referred to herein individually as a “Party” or collectively as the “Parties”.
AMENDMENT NO. 1 TO THE LICENSE AGREEMENTThe License Agreement • July 15th, 2020 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations
This Amendment No.1 to the License Agreement (the “Amendment”) is effective as of date of last signature set forth below (the “Amendment Effective Date”), by and between:
FOURTH AMENDMENT TO THE LICENSE AGREEMENTThe License Agreement • January 14th, 2005 • Euro Disney S C A • Services-membership sports & recreation clubs
FOURTH AMENDMENT, dated as of November 30, 2004, to the license agreement dated as of February 28, 1989, as amended by a First Amendment dated as of January 1, 1991, a Second Amendment dated as of March 1, 1993 and a Third Amendment dated as of June 10, 1994 (the “License Agreement”).
AMENDMENT TO THE SECOND AMENDMENT TO THE LICENSE AGREEMENTThe License Agreement • May 14th, 2020 • Immune Therapeutics, Inc. • Pharmaceutical preparations
This amendment (“Third Amendment”) to the Second Amendment to The License Agreement is effective December 31, 2018 (“Effective Date”) by and between Cytocom Inc., a for profit corporation duly organized and existing under the laws of the Commonwealth of Delaware, having an office at 3001 Aloma Ave, Winter Park, FL 32792 (“CYTO”), and Immune Therapeutics Inc., a Florida Corporation, having an office at 2431 Aloma Ave #124 Winter Park, FL 32792 (“IMUN and or Company or Licensee”). CYTO and Licensee may each be referred to individually as “Party” and collectively as “Parties”.
AMENDMENT TO THE LICENSE AGREEMENT BY AND BETWEEN INDEVUS PHARMACEUTICALS, INC. AND PALIGENT INC.The License Agreement • May 13th, 2003 • Indevus Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS AMENDMENT, dated as of April 10, 2003, by and between Paligent Inc., formerly Heavenlydoor.com, Inc. (“Paligent”) and Indevus Pharmaceuticals, Inc., formerly Interneuron Pharmaceuticals, Inc. (“Indevus”), amends the License Agreement effective as of June 14, 2000 (the “License Agreement”) by and between Paligent and Indevus.
AMENDMENT NO. 2 TO THE LICENSE AGREEMENT FOR TELEVISION BROADCAST RIGHTSThe License Agreement • May 5th, 2020
FRANCE TELEVISIONS DISTRIBUTION, located Bâtiment EOS, 37/45 Quai du Président Roosevelt - 92130 Issy les Moulineaux, France, VAT # FR59379518368, hereinafter referred to as "FTD ", FR59379518368, represented by its CEO, Julien Verlgy on one part, and
AMENDMENT #1 TO THE LICENSE AGREEMENTThe License Agreement • May 9th, 2012 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances)
This Amendment #1 to the AGREEMENT (“Amendment #1) is made by and between PAION Holdings UK Ltd (Company Number SC 166791) (“Paion” ) whose principal place of business is at Compass House, Vision Park, Chivers Way, Histon, Cambridge CB24 9ZR, UK, and Acorda Therapeutics, Inc. (“Acorda” or “LICENSEE”), a corporation organized and existing under the laws of the State of Delaware and having a principal place of business at 15 Skyline Drive, Hawthorne, NY 10532.
THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL...The License Agreement • August 26th, 2014 • NeuroSigma, Inc. • Electromedical & electrotherapeutic apparatus
This first amendment (the “First Amendment”), dated January 9, 2011 (the “Effective Date”), is made by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (“The Regents”), a California corporation having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through the offices of The University of California, Los Angeles located at 11000 Kinross Avenue, Suite #200, Los Angeles, CA 90095-1406 and NEUROSIGMA, INC. (“Licensee”) having a principal place of business at 10960 Wilshire Boulevard, Suite 1230, Los Angeles, CA, 90024 and amends the license agreement with Licensee, dated July 26, 2010 with UC Agreement Control Number 2011-04-0059 (the “License Agreement”), in accordance with the terms and conditions of this First Amendment.
AMENDMENT NO. 1 TO THE LICENSE AGREEMENTThe License Agreement • February 27th, 2024 • Vaxcyte, Inc. • Biological products, (no disgnostic substances)
This first amendment to the License Agreement ("Amendment No. 1") is made by and between Sutrovax, Inc., having an address at 353 Hatch Drive, Foster City, California 94404 ("LICENSEE") and The Regents of the University of California, a California corporation having its administrative offices at 1111 Franklin Street, Oakland, California 94607 ("UNIVERSITY"), as represented by its San Diego campus having an address at University of California San Diego, Office of Innovation and Commercialization, Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093.
FIRST AMENDMENT TO THE LICENSE AGREEMENTThe License Agreement • September 15th, 2023 • Acesis Holdings Corp. • Biological products, (no disgnostic substances) • Quebec
This First Amendment (the “Amendment”), dated as set forth on the signature page below and effective as of January 6, 2016 is being entered into between: IASO BioMed, Inc., a Colorado corporation (the “Licensee”), and herein acting and represented by its duly authorised representatives (hereinafter, called “Licensee”), and The Royal Institution for the Advancement of Learning/McGill University, a Canadian University and herein acting and represented by its duly authorised representatives (hereinafter, called “McGill”), and amends the License Agreement, effective as of January 6, 2016 between McGill and Licensee (the “License Agreement”). Capitalized terms used herein but not defined shall have the meanings ascribed to them in the License Agreement.
THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL...The License Agreement • August 26th, 2014 • NeuroSigma, Inc. • Electromedical & electrotherapeutic apparatus
THIS THIRD AMENDMENT (the “Third Amendment”), dated August 30, 2012 (the “Effective Date”), is made by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (“The Regents”), a California corporation having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through the offices of The University of California, Los Angeles located at 11000 Kinross Avenue, Suite #200, Los Angeles, CA 90095-1406 and NEUROSIGMA, INC. (“Licensee”) having a principal place of business at 10960 Wilshire Boulevard., Suite 1230, Los Angeles, CA, 90024 and amends the license agreement with Licensee, dated July 26, 20 l 0 with UC Agreement Control Number 2011-04-0059, the First Amendment dated January 9, 2011, and the Second Amendment dated July 29, 2011 (the “License Agreement”), in accordance with the terms and conditions of this Third Amendment.
CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. DOUBLE ASTERISKS DENOTE SUCH OMISSIONS. AMENDMENT NO. 1 TO THE LICENSE AGREEMENTThe License Agreement • September 21st, 2015 • Edge Therapeutics, Inc. • Pharmaceutical preparations
THIS AMENDMENT (the “Amendment No. 1”), effective as of September 21, 2015 to the October 20, 2010 License Agreement (the “Agreement”) by and between Evonik Corporation (assignee of this Agreement by SurModics Pharmaceuticals, Inc.), an Alabama Corporation, with a principal place of business at 299 Jefferson Road, Parsippany, New Jersey 07054 and a facility at 750 Lakeshore Parkway, Birmingham, Alabama 35211 (“formerly “Evonik Degussa Corporation” and hereinafter “Evonik”) and Edge Therapeutics, Inc., a Delaware corporation having a place of business at 200 Connell Drive, Suite 1600, Berkeley Heights, New Jersey 07922 (“Edge”) is made by and between Evonik and Edge.
AMENDMENT NO. 3 TO THE LICENSE AGREEMENT BETWEEN INTRINSIC MEDICINE, INC. (FKA LUPA BIO, INC.) AND THE REGENTS OF THE UNIVERSITY OF CALIFORNIAThe License Agreement • April 8th, 2022 • Intrinsic Medicine, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 3 to the License Agreement (this “Amendment No. 3”) is entered into by and between Intrinsic Medicine, Inc. (fka Lupa Bio, Inc.) (hereinafter “LICENSEE”) and the Regents of the University of California (“UNIVERSITY”) represented by its San Diego campus (“UC San Diego”), each referred to herein as a “Party”, or collectively as the “Parties”. Capitalized terms used herein and not otherwise defined have the meanings ascribed to them in the License Agreement.
AMENDMENT NO. 5 TO LICENSE AGREEMENT REGENTS OF THE UNIVERSITY OF MICHIGAN AND ONCOMED PHARMACEUTICALS, INC.The License Agreement • May 11th, 2012 • OncoMed Pharmaceuticals Inc
THIS AMENDMENT NO. 5 TO THE LICENSE AGREEMENT (“Amendment”) is made effective as of March 12th, 2007 (the “Amendment Date”) and is entered into by and between THE REGENTS OF THE UNIVERSITY OF MICHIGAN, a constitutional corporation of the State of Michigan (“Michigan”) and ONCOMED PHARMACEUTICALS, INC., a Delaware corporation having offices at 800 Chesapeake Drive, Redwood City, CA 94063 (“OncoMed”) to amend their License Agreement dated January 5, 2001, as amended by Amendment Number 1 to the License Agreement dated as of July 21, 2004, as amended by Amendment Number 2 to the License Agreement dated as of August 13, 2004, as amended by Amendment Number 3 to the License Agreement dated as of March 31st, 2005, and as amended by Amendment Number 4 to the License Agreement dated as of December 12, 2005 (collectively “License Agreement”).
FIRST AMENDMENT TO THE LICENSE AGREEMENTThe License Agreement • November 14th, 2011 • Health Discovery Corp • Patent owners & lessors
This First Amendment to the License Agreement (“First Amendment”) is entered into, and made effective on, August 4, 2011 by and between Health Discovery Corporation, a Georgia corporation (“HDC”), having its principal place of business at 2 East Bryan Street, Suite #610, Savannah, GA 31401 (“HDC”), and Abbott Molecular Inc., a Delaware corporation having its principal place of business at 1300 East Touhy Avenue, Des Plaines, IL, 60018 (“Abbott”), collectively referred to as the “Parties.”
AMENDMENT NO. 3 TO THE LICENSE AGREEMENTThe License Agreement • May 5th, 2020 • XOMA Corp • Pharmaceutical preparations • California
THIS AMENDMENT NO. 3 (this "Amendment") to that certain License Agreement dated as of December 6, 2017, by and between XOMA (US) LLC, a Delaware limited liability company ("XOMA"), having an address of 2200 Powell Street, Suite 310, Emeryville, CA 94608 and Rezolute, Inc. (formerly known as AntriaBio, Inc.), a Delaware corporation ("Rezolute"), having an address of 201 Redwood Shores Parkway, Redwood City, CA 94065, as amended by Amendment No. 1 dated March 30, 2018, and further amended by Amendment No. 2 dated January 7, 2019 (collectively, the "License Agreement"), is entered into by and between XOMA and Rezolute effective as of March 31, 2020 (the "Effective Date"). Each of XOMA and Rezolute may be referred to herein as a "Party", or jointly as the "Parties". Terms used but not otherwise defined herein shall have the meanings ascribed to them in the License Agreement.
FOURTH AMENDMENT TO THE LICENSE AGREEMENTThe License Agreement • November 2nd, 2012 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances)
This FOURTH AMENDMENT TO THE LICENSE AGREEMENT (the “Fourth Amendment”) is made and entered into as of September 14, 2012 (the “Fourth Amendment Effective Date”) by and between SANGAMO BIOSCIENCES, INC., a Delaware corporation having its principal place of business at Point Richmond Tech Center, 501 Canal Boulevard, Suite A100, Richmond, California 94804 (“Sangamo”), and SIGMA-ALDRICH CO. LLP, a Delaware limited liability company having its principal place of business at 3050 Spruce Street, St. Louis, MO 63103 (“Sigma”). Sigma and Sangamo are individually referred to herein as a “Party” or collectively as the “Parties.”
FIRST AMENDMENT TO THE LICENSE AGREEMENTThe License Agreement • January 30th, 2017
This is the First Amendment to the License Agreement between FIRST DATABANK, INC. (FDB) and County of San Bernardino d/b/a Arrowhead Regional Medical Center (LICENSEE) dated July 1, 2014. FDB and LICENSEE agree to modify specific terms of the Agreement effective July 1, 2017 (“First Amendment Effective Date”). Except as provided below, all of the terms and provisions of the Agreement remain in full force and effect.
SECOND AMENDMENT TO THE LICENSE AGREEMENTThe License Agreement • May 11th, 2022
This Second Amendment (the “Amendment”) to the License Agreement is made and entered into this day of , 2022, between the City of Grand Rapids, Minnesota (“Licensor”) and Waste Management of Minnesota, Inc. (“Licensee”).
AMENDMENT NO. 3 TO THE LICENSE AGREEMENTThe License Agreement • February 28th, 2022 • Compugen LTD • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 3 TO THE LICENSE AGREEMENT (this “Amendment”) is made and entered into as of August 4th, 2021 (the “Amendment Effective Date”), by and between MedImmune Limited, a company incorporated in England and a member of the AstraZeneca Group having an address of Milstein Building, Granta Park, Abington, Cambridge, CB21 6GH (“MedImmune”) and Compugen Ltd., a an Israeli company, having an address of Azrieli Center, 26 Harokmim Street, Building D, Holon 5885849, Israel (“Compugen”). MedImmune and Compugen are each referred to in this Amendment as a “Party” and collectively, as the “Parties”.
AMENDMENT TO THE LICENSE AGREEMENTThe License Agreement • August 22nd, 2005 • Apogee Technology Inc • Semiconductors & related devices
This AMENDMENT TO THE LICENSE AGREEMENT (the “Amendment”) is made and entered into by and between STMicroelectronics N.V., a Dutch corporation (“ST”), and APOGEE Technology Inc., a Delaware corporation (“Apogee”).
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. SECOND AMENDMENT TO THE LICENSE AGREEMENTThe License Agreement • March 1st, 2017 • Acceleron Pharma Inc • Biological products, (no disgnostic substances)
This Second Amendment (“Second Amendment”), effective as of November 7, 2016, between Acceleron Pharma Inc., having its principal place of business at 128 Sidney Street, Cambridge, MA 02139 (“Licensee”) and Beth Israel Deaconess Medical Center, having its principal place of business at 330 Brookline Avenue, Boston, MA 02215 (the “BIDMC”) amends the License Agreement between BIDMC and Licensee, dated June 21, 2012 as amended on October 6, 2015 (the “Agreement”). Together BIDMC and Licensee are the “Parties” and each is a “Party”.
AMENDMENT NO. 1 TO THE LICENSE AGREEMENT BETWEEN LUPA BIO, INC. AND THE REGENTS OF THE UNIVERSITY OF CALIFORNIAThe License Agreement • April 8th, 2022 • Intrinsic Medicine, Inc. • Biological products, (no disgnostic substances) • California
This Amendment No. 1 to the License Agreement (this “Amendment No. 1”) is entered into by and between Lupa Bio, Inc. (hereinafter “LICENSEE”) and the Regents of the University of California (“UNIVERSITY”) represented by its San Diego campus (“UC San Diego”), each referred to herein as a “Party”, or collectively as the “Parties”. Capitalized terms used herein and not otherwise defined have the meanings ascribed to them in the License Agreement.
PRC AMENDMENT TO THE SECOND AMENDMENT TO THE LICENSE AGREEMENTThe License Agreement • May 14th, 2020 • Immune Therapeutics, Inc. • Pharmaceutical preparations
This amendment to the Second Amendment to The License Agreement (herein referred to as the “PRC Amendment”) is effective December 31, 2018 (“Effective Date”) by and between Cytocom, Inc., a for profit corporation duly organized and existing under the laws of the Commonwealth of Delaware, having an office at 3001 Aloma Ave, Winter Park, FL 32792 (“CYTO”), and Immune Therapeutics, Inc., a Florida Corporation, having an office at 2431 Aloma Ave #124 Winter Park, FL 32792 (“IMUN and or Company or Licensee”). CYTO and Licensee may each be referred to individually as “Party” and collectively as “Parties”.
AMENDMENT TO THE LICENSE AGREEMENTThe License Agreement • July 21st, 2022 • New York
Each of MSD and MPP is referred to in this Agreement as a “Party”. MSD and MPP are collectively referred to in this Agreement as the “Parties”.
AMENDMENT #3 TO THE LICENSE AGREEMENTThe License Agreement • November 27th, 2013 • Inogen Inc • Orthopedic, prosthetic & surgical appliances & supplies
This Amendment #3 to the License Agreement (“Amendment #3”) is entered into by and between AIR PRODUCTS AND CHEMICALS, INC (“Air Products”), a corporation organized and existing under the laws of the State of Delaware and having its principal office at 7201 Hamilton Boulevard, Allentown PA 18195 and INOGEN, INC. (“Inogen”), a corporation organized and existing under the laws of the State of Delaware and having its principal office at 326 Bollay Drive, Goleta, California 93117 effective as of March 22, 2011 (the “Effective Date of Amendment #3”).
AMENDED AND RESTATED ANNEX A TO THE LICENSE AGREEMENTThe License Agreement • July 2nd, 2021 • Dermata Therapeutics, Inc. • Pharmaceutical preparations
THIS ANNEX (this “Annex”) A is attached to THE LICENSE AGREEMENT dated March 31, 2017 by and between Villani, Inc., a Delaware corporation with mailing address of 220 Newport Center Dr., Suite 11-578, Newport Beach, CA 92660 (the “Licensor”) and Dermata Therapeutics, LLC., a Delaware limited liability company having a principal place of business at 12340 El Camino Real, Suite 425, San Diego, California, 92130 (“Dermata”) as of this 23nd day of November 2018. This Annex replaces and supersedes the Annex A attached to the License Agreement on March 31, 2017.
AMENDMENT NO. 3 TO THE LICENSE AGREEMENTThe License Agreement • May 14th, 2020 • Rezolute, Inc. • Pharmaceutical preparations • California
THIS AMENDMENT NO. 3 (this "Amendment") to that certain License Agreement dated as of December 6, 2017, by and between XOMA (US) LLC, a Delaware limited liability company ("XOMA"), having an address of 2200 Powell Street, Suite 310, Emeryville, CA 94608 and Rezolute, Inc. (formerly known as AntriaBio, Inc.), a Delaware corporation ("Rezolute"), having an address of 201 Redwood Shores Parkway, Redwood City, CA 94065, as amended by Amendment No. 1 dated March 30, 2018, and further amended by Amendment No. 2 dated January 7, 2019 (collectively, the "License Agreement"), is entered into by and between XOMA and Rezolute effective as of March 31, 2020 (the "Effective Date"). Each of XOMA and Rezolute may be referred to herein as a "Party", or jointly as the "Parties". Terms used but not otherwise defined herein shall have the meanings ascribed to them in the License Agreement.
THIRD AMENDMENT TO the LICENSE AGREEMENTThe License Agreement • February 2nd, 2024 • Lirum Therapeutics, Inc. • Pharmaceutical preparations
This Third Amendment to the License Agreement (this “Third Amendment”) is made and entered into this 12th day of January 2024, by and among IGF Oncology, LLC, a Delaware limited liability company (“IGF”), and Lirum Therapeutics, Inc., a Delaware corporation (“LIRUM”). IGF and LIRUM are from time to time referred to herein individually as a “Party” or collectively as the “Parties”.
EURO DISNEYLAND PROJECT IN FRANCEThe License Agreement • January 14th, 2005 • Euro Disney S C A • Services-membership sports & recreation clubs
SCHEDULE I - List of current subsidiaries, direct and indirect, of Euro Disney S.C.A., Euro Disney Associés S.C.A. and EDL Hôtels S.C.A. (after the Contribution)
ContractThe License Agreement • November 2nd, 2017
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
AMENDMENT TO THE LICENSE AGREEMENT BY AND BETWEEN INDEVUS PHARMACEUTICALS, INC. AND PALIGENT INC.The License Agreement • April 18th, 2003 • Paligent Inc • Biological products, (no disgnostic substances) • New York
THIS AMENDMENT, dated as of April 10, 2003, by and between Paligent Inc., formerly Heavenlydoor.com, Inc. (“Paligent”) and Indevus Pharmaceuticals, Inc., formerly Interneuron Pharmaceuticals, Inc. (“Indevus”), amends the License Agreement effective as of June 14, 2000 (the “License Agreement”) by and between Paligent and Indevus.
